Alpha Tau Medical (DRTS) Depreciation & Amortization (CF) (2021 - 2022)
Alpha Tau Medical (DRTS) posted Depreciation & Amortization (CF) of $244000.0 for Q2 2022, up 5.63% sequentially from $231000.0 in Q1 2022.
Powered by 
Analysis
Alpha Tau Medical (DRTS) Depreciation & Amortization (CF) (2021 - 2022) Analysis & Trends
Alpha Tau Medical has reported Depreciation & Amortization (CF) for 2 years, with the latest figure at $244000.0 in Q2 2022.
- Quarterly Depreciation & Amortization (CF) changed N/A year-over-year to $244000.0 in Q2 2022, while the trailing twelve-month figure through Mar 2023 was $244000.0 (up 5.63% YoY) and the FY2025 annual result came in at $1.2 million, up 11.8% from the prior year.
- Depreciation & Amortization (CF) climbed to $244000.0 in Q2 2022 per DRTS's latest filing, from $231000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $244000.0 in Q2 2022 and troughed at $164000.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Alpha Tau Medical | 1.21 Bn | 1.11 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2022 | 244,000.00 |
| Mar 31, 2022 | 231,000.00 |
| Mar 31, 2021 | 164,000.00 |